Currently at least 75% of patients with severe aplastic anaemia can be successfully transplanted using a matched unrelated donor (UD) haematopoietic SCT (HSCT). For children, outcomes are similar to matched sibling donor (MSD) HSCT. This improvement in outcome over time is likely due to improved HLA tissue typing to identify better matched donors, improvements in the conditioning regimen, particularly fludarabine-based regimens, and improved supportive care. Graft rejection occurs in B15% of adults, but is less frequent in children. Chronic GVHD remains a concern but may be reduced by using Alemtuzumab instead of ATG. UD HSCT should be considered early after failure to respond to one course of immunosuppressive therapy, but for children who lack a MSD up front matched UD HSCT may be considered. (2013) 48, 198-200; doi:10.1038/bmt.2012.233; published online 26 November 2012
The outcome of unrelated donor (UD) transplants for patients with aplastic anemia (AA) has improved in the last decade.
1,2 Better selection of HLA-matched donors has probably had a major role, but also significant changes in the conditioning regimen have occurred, including the use of fludarabine (FLU)-based conditioning, the addition of low-dose (2 Gy) [3] [4] [5] [6] TBI in adults, and the use of Alemtuzumab as an alternative to ATG. [7] [8] [9] [10] OS is currently 475%. 6, 10 Results of UD transplants have improved to such an extent that treatment recommendations should be adapted: UD transplantation is now considered after failure to respond to one course of immunosuppressive therapy, and in children UD haematopoietic SCT (HSCT) may be considered as first line treatment in severe aplastic anaemia (SAA).
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Centres match either for A, B, C and DRB1 at the allelic level, looking for 8/8 matched donors 12 or for DQ looking for a 10/10 match. In a recent European BMT (EBMT) analysis, we showed an effect of mismatching (o8/8 vs 8/8 match) only for patients prepared with FLU-CY and ATG (FCA), but not for patients receiving FCA supplemented with low-dose TBI 2 Gy (FCA-TBI). 13 In general, an 8/8 (A, B, C and DRB1) matched donor would be ideal, but a 7/8 (or 9/10) match would probably be also acceptable if low-dose TBI is used. [14] [15] [16] The combination of FLU-CY and ATG is used most often for the conditioning regimen in UD HSCT for acquired AA, 5, 6 although Alemtuzumab is an emerging alternative option to ATG (FCC). [7] [8] [9] [10] Low-dose TBI, 2 or 3 Gy, was added following the Japanese and USA studies. 3, 4 The dose of CY was originally set at 300 mg/ m 2 Â 4. 5, 6 This was associated with a significant risk of rejection, so the current indication is to increase the dose of CY to 120 mg/kg. The working party SAA currently recommends FLU 30 mg/m 2 Â 4, CY 30 mg/kg Â 4 and ATG. TBI (2 Gy) can be added on day À 1 for patients aged 414 years, 6 but can be considered also for children sensitized after numerous blood transfusions. Alemtuzumab used with FLU and CY 300 mg/m 2 Â 4 (FCC) has recently been reported to show encouraging results with a very low incidence of chronic GVHD and can be considered as a substitute to ATG. 10 Using the FLU-CY and ATG regimen, prophylaxis of GVHD is CSA with low-dose MTX on days þ 1, þ 3, þ 6 and þ 11. CSA is continued for 9 months followed by a tapering of the dose over 3 months if chimerism is satisfactory. For FCC conditioning, CSA alone is sufficient post graft immunosuppression and there is no indication for adding in MTX. In the EBMT study, acute GVHD grade II-IV was low (18%) and chronic GVHD was more frequent, as expected, when TBI 2 Gy was added to FCA (50% vs 27%), see Table 1: 7 this was particularly true when PB was used as a source of stem cells. The risk of extensive chronic GVHD is 3% for BM and 20% for PB. In contrast, using FCC, the risk of acute GVHD is 14% and chronic GVHD 4%. 10 A study from the Center for International Blood and Marrow Transplant Research of 296 SAA patients transplanted from UD compared 225 patients receiving PBSC and 71 BM cells. Haematological recovery was similar between the two groups; there was more acute GVHD with PBSC but no difference in chronic GVHD. 17 OS was lower using PBSC. A recent EBMT analysis of 451 UD transplants performed with BM stem cells show a 10-year OS of 67% compared with 48% for 153 UD PBSC Transplantation (Po0.0001; A Bacigalupo, on behalf of the EBMT SAAWP, unpublished data). Thus, BM is the favoured stem cell source. However, PBSC continue to be used by many centres because of the convenience and deskilling of operators resulting in low stem cell dose obtained from BM harvests, which increases the risk of graft rejection. 12 The most relevant predictor of outcome is the interval between diagnosis and transplant, with a relative risk of death of 4.4, if the transplant was delayed beyond 2 years. All of the rejection-related deaths were in patients grafted beyond 2 years. For patients grafted within 2 years, the actuarial 5-year survival is overall 87, and 92% for patients (n ¼ 24) grafted beyond 2004.
Using the FLU-CY and ATG (FCA) regimen, the cumulative incidence of graft failure was 17% in the EBMT study. 6 Risk factors for graft failure were patients with a longer interval from diagnosis to transplant (42 years) had a trend for a higher risk of graft failure (22%) compared with patients grafted o1 year (12%) or between 1 and 2 years from diagnosis (14%; P ¼ 0.3). The median number of infused nucleated cells was 4.5 vs 4.24 Â 10 8 /kg for patients with or without sustained engraftment. Graft failure was seen in 1/10 (10%) peripheral blood (PB) transplants vs 15/88 (17%) BMTs. For FCC regimen, graft failure occurred in 12, 9.5% for matched sibling donor and 14.5% for UD HSCT. Mixed donor chimersim post FCC occurs frequently. Full donor chimerism in unfractionated blood occurred in only 42%, and no patient achieved CD3 full donor chimerism. Stable mixed T-cell chimerism was associated with the absence of chronic GVHD and sustained myeloid engraftment, 10 see Figure 1 . In the EBMT study, 6 the cumulative incidence of EBVlymphoproliferative disorder was 4%. There are two different strategies to prevent EBV-lymphoproliferative disorder: one is to treat pre-emptively patients showing an increase in EBV-DNA, above a given cutoff (1000 copies/10 5 mononuclear cells or 10 000 copies/ml). 18 The second strategy is to use prophylactic Rituximab on day þ 5. 13 Prophylactic Rituximab may also reduce the risk of GVHD. Using FCC regimen, EBV viraemia was seen in 8% of patients and lymphoproliferative disorder in 4%. CMV reactivation occurred in 18% patients, but with only once case (2%) of CMV disease. 10 Using a conditioning regimen FCA or FCA-TBI, the actuarial 10-year survival was overall 75 and 83% for patients grafted beyond 2004, 6 see Figure 2 . For FCC regimen, 2-year OS is 83%, see Figure 3 . 10 Combining UD and matched sibling donor HSCT using FCC, it was shown for the first time that comorbidity index impacts on OS, and encouraging OS of 70% for patients aged 450 years. 10 For children, outcomes following UD HSCT are similar to matched sibling donor HSCT, 19 hence the move to consider UD HSCT as firstline therapy for SAA in the absence of a matched sibling donor. 
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Days following transplantation (OS) Survival Figure 3 . OS using FCC, for UD and matched sibling donor (MSD).
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